Braveheart Bio, Inc. (BRVE) News
Track canonical SquawkNews coverage tagged to BRVE, Braveheart Bio, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 13 indexed stories across 7 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
BRVE - Braveheart Bio to Participate in Stifel Cardiometabolic Forum
BRVE - Braveheart Bio to Participate in Stifel Cardiometabolic Forum
NEWS | Sep 16, 2026, 08:30 PM UTC
L
BRVE starts Phase 3 for BHB-1893; cash funds into 2029
BRVE initiated Phase 3 trials for BHB-1893 in oHCM and nHCM. Cash reserves of $527.3 million post-IPO are expected to fund operations into 2029. Q2 2026 net loss widened to $18.6 million.
EARNINGS | Sep 08, 2026, 08:14 PM UTC
L
Braveheart Bio reports Q2 2026 revenue of $0, EPS $(2.51), 10-Q
Braveheart Bio reported second-quarter 2026 revenue of $0 and EPS of $(2.51), with no product revenue and a wider net loss as late-stage development and trial activities ramped.
EARNINGS | Sep 08, 2026, 08:14 PM UTC
M
Braveheart Bio reports 2Q loss of $2.51 per share
Braveheart Bio reported a 2Q loss of $2.51 per share, according to TradingView News.
EQUITY | Sep 08, 2026, 08:04 PM UTC
L
Braveheart Bio reports Q2 2026 financial results and business update
Braveheart Bio reported second-quarter 2026 financial results and provided a business update.
EARNINGS | Sep 08, 2026, 08:03 PM UTC
L
Braveheart Bio to participate in Cantor Global Healthcare Conference
Braveheart Bio, Inc. announced it will participate in the Cantor Global Healthcare Conference.
EQUITY | Sep 01, 2026, 08:37 PM UTC
L
BRVE - Braveheart Bio to Participate in Cantor Global Healthcare Conference
BRVE - Braveheart Bio to Participate in Cantor Global Healthcare Conference
EQUITY | Sep 01, 2026, 08:30 PM UTC
L
Braveheart Bio initiated at Buy by Goldman Sachs
TradingView News reports Braveheart Bio was initiated at Buy by Goldman Sachs.
EQUITY | Aug 31, 2026, 06:12 PM UTC
L
Braveheart Bio started Buy at TD Cowen
Braveheart Bio was initiated with a Buy rating by TD Cowen.
EQUITY | Aug 31, 2026, 02:42 PM UTC
L
Braveheart Bio Initiated at Buy by Jefferies
Braveheart Bio Initiated at Buy by Jefferies
EQUITY | Aug 31, 2026, 02:32 PM UTC
H
Braveheart Bio Prices Upsized IPO
Braveheart Bio announces IPO pricing
EQUITY | Aug 06, 2026, 02:33 AM UTC
H
Opening Day: Scribe Therapeutics makes strong trading debut
Scribe Therapeutics makes its public debut above issue price as the CRISPR drug developer opened for trading last week. The biotech entered the market with cardiometabolic programs at the forefront and early momentum beh
MNA | Jul 27, 2026, 03:21 PM UTC
L
Opening Day: IPO momentum continues with Standard Nuclear, Csquare
Standard Nuclear, QumulusAI and Csquare stepped onto the public stage last week, kicking off a diverse slate of debuts spanning next generation nuclear fuel, distributed AI compute and large scale data centers. LATEST IP
EARNINGS | Jul 20, 2026, 03:00 PM UTC